Your browser doesn't support javascript.
loading
Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial.
Rodon Ahnert, J; Tan, D S-W; Garrido-Laguna, I; Harb, W; Bessudo, A; Beck, J T; Rottey, S; Bahary, N; Kotecki, N; Zhu, Z; Deng, S; Kowalski, K; Wei, C; Pathan, N; Laliberte, R J; Messersmith, W A.
  • Rodon Ahnert J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: JRodon@mdanderson.org.
  • Tan DS; Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
  • Garrido-Laguna I; Division of Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, USA.
  • Harb W; Syneos Health, Morrisville, USA.
  • Bessudo A; California Cancer Associates for Research and Excellence, San Diego, USA.
  • Beck JT; Highlands Oncology, Springdale, USA.
  • Rottey S; Department of Medical Oncology, UZ Gent, Gent, Belgium.
  • Bahary N; AHN Cancer Institute, Allegheny Health Network, Pittsburgh, USA.
  • Kotecki N; Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium.
  • Zhu Z; Pfizer, San Diego, USA.
  • Deng S; Pfizer, San Diego, USA.
  • Kowalski K; Pfizer, San Diego, USA.
  • Wei C; Pfizer, Groton, USA.
  • Pathan N; Pfizer, San Diego, USA.
  • Laliberte RJ; Pfizer, Cambridge, USA.
  • Messersmith WA; Division of Medical Oncology, University of Colorado Cancer Center, Aurora, USA.
ESMO Open ; 8(4): 101584, 2023 08.
Article en En | MEDLINE | ID: mdl-37379764
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adenocarcinoma / Inhibidores de Poli(ADP-Ribosa) Polimerasas Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adenocarcinoma / Inhibidores de Poli(ADP-Ribosa) Polimerasas Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article